Cystic fibrosis (CF) patients are frequently treated with aminoglycosides, a powerful group (class) of antibiotics, due to the common presence of (Gram-stain negative) bacteria which can be resistant to (unaffected by) most antibiotics. If not treated with the appropriate antibiotics, these bacteria may contribute to pulmonary to lung infections that lead to severe breathing complications. Miller Children’s Hospital currently has a pharmacy-regulated dosing guideline for determining the appropriate utilization of extended-interval tobramycin for our pediatric patients with cystic fibrosis. This Extended-Interval Tobramycin (EIT) guideline was implemented in 2006, but has yet to be audited. This study will evaluate how well the guideline is being adhered to, evaluate how well adhering to the guideline improves outcome and assess if a revision of the guideline is necessary.
Retrospective Evaluation of the Performance of an Extended-Interval Tobramycin Guideline for Pediatric Cystic Fibrosis Patients
Robert TindulaConducted at:
Miller Children‘s Hospital Long BeachCurrently enrolling additional patients: